Loading
Mycophenolate Mofetil · Regulatory label update
U.S. Food and Drug Administration · July 29, 2026
An action by a regulator. Authoritative on labelling and availability.
The FDA approved a supplemental Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil 250 mg capsules (generic, sponsor Hikma) on July 29, 2026. This regulatory action requires additional safety monitoring and communication measures but does not report clinical trial results or efficacy data.
Regulatory label update.
Supplemental REMS approval granted for mycophenolate mofetil 250 mg capsule oral formulation Approval date: July 29, 2026 Sponsor: Hikma Pharmaceuticals
This record does not contain clinical trial results, efficacy data, or comparative safety outcomes. No information on the reason for the REMS supplement or what safety issue prompted it is provided.
This record indicates that mycophenolate mofetil capsules are now subject to a REMS program, meaning prescribers and patients must comply with specific risk mitigation requirements (such as certification, restricted distribution, or monitoring protocols). Clinicians should verify current REMS requirements before dispensing or prescribing.
FDA supplemental approval for a REMS (Risk Evaluation and Mitigation Strategy) on an established generic drug; a regulatory action, not a clinical trial.
Quoted from the source exactly as published.
This record indicates that mycophenolate mofetil capsules are now subject to a REMS program, meaning prescribers and patients must comply with specific risk mitigation requirements (such as certification, restricted distribution, or monitoring protocols). Clinicians should verify current REMS requirements before dispensing or prescribing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Drugs@FDA record for application ANDA065410. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: HIKMA. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.